miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

BACKGROUND: Drug resistance hampers the efficient treatment of malignancies, including advanced stage ovarian cancer, which has a 5-year survival rate of only 30 %. The molecular processes underlying resistance have been extensively studied, however, not much is known about the involvement of microR...

Descripción completa

Detalles Bibliográficos
Autores principales: van Jaarsveld, Marijn T. M., van Kuijk, Patricia F., Boersma, Antonius W. M., Helleman, Jozien, van IJcken, Wilfred F., Mathijssen, Ron H. J., Pothof, Joris, Berns, Els M. J. J., Verweij, Jaap, Wiemer, Erik A. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650519/
https://www.ncbi.nlm.nih.gov/pubmed/26576679
http://dx.doi.org/10.1186/s12943-015-0464-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650519/
https://www.ncbi.nlm.nih.gov/pubmed/26576679
http://dx.doi.org/10.1186/s12943-015-0464-4

Ejemplares similares